Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.104 USD | -0.76% | -15.51% | -41.72% |
Mar. 25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2022 | 861K | Sales 2023 | 107K | Capitalization | 5.8M |
---|---|---|---|---|---|
Net income 2022 | -115M | Net income 2023 | -74M | EV / Sales 2022 | 5.01 x |
Net cash position 2022 | 18.68M | Net Debt 2023 | 5M | EV / Sales 2023 | 101 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.08
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.52% |
1 day | -2.36% | ||
1 week | -15.51% | ||
Current month | -6.08% | ||
1 month | -14.30% | ||
3 months | -17.49% | ||
6 months | -45.00% | ||
Current year | -41.72% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 2.104 | -0.76% | 3 187 |
24-05-08 | 2.12 | -2.75% | 25,154 |
24-05-07 | 2.18 | -2.24% | 21,386 |
24-05-06 | 2.23 | -3.04% | 250,502 |
24-05-03 | 2.3 | -7.63% | 53,342 |
Delayed Quote Nasdaq, May 09, 2024 at 09:49 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-41.72% | 3.4M | |
+23.72% | 46.71B | |
+48.83% | 41.8B | |
-1.06% | 41.52B | |
-3.42% | 29.55B | |
+10.60% | 25.78B | |
-20.94% | 19.26B | |
+0.01% | 12.14B | |
-0.41% | 12.08B | |
+26.80% | 11.98B |
- Stock Market
- Equities
- FNCH Stock